Free Trial

Enveric Biosciences Q2 2023 Earnings Report

Enveric Biosciences logo
$1.47 -0.13 (-8.13%)
As of 03/28/2025 04:00 PM Eastern

Enveric Biosciences EPS Results

Actual EPS
-$45.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enveric Biosciences Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Enveric Biosciences Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Enveric Biosciences CEO Issues Letter to Shareholders
This Biotech Soared On Key Announcement
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

View Enveric Biosciences Profile

More Earnings Resources from MarketBeat